Caliper Technologies - CALP Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Caliper Technologies - CALP

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: mopgcw	1/15/2006 6:34:33 AM
	Read Replies (1) of 114

Barron's: Caliper Life Sciences - CALP-NNM Accumulate - Price 6.45 on Jan. 11 by Think Equity Caliper [recently] preannounced full-year revenue guidance of $86 to $88 million, narrowing its previous revenue guidance between $84 to $90 million and in-line with our revenue estimate of $86 million. Management reiterated it expects Caliper to [show] positive cash flow for this past 4Q....We are not changing our 4Q05 and full-year 2005 earnings-per-share EPS estimates of (5 cents) and (35 cents), respectively (excluding non-cash amortization). Our outlook for Caliper remains positive. We believe collaborations with Affymetrix (AFFX), Bio-Rad (BIO), as well as the NovaScreen acquisition, should drive greater LabChip adoption. Our $8 price target is based on a forward price/earnings multiple of 35 times our 2008 EPS estimate discounted back at a 25% rate to year-end 2006. Tables: New Coverage Upgrades & DowngradesCALP [develops and commercializes] life-science instruments and related consumables used in the pharmaceutical and biotechnology industries worldwide. It uses liquid handling, automation, and LabChip microfluidics technologies to create products for use in drug discovery and development, genomics and proteomics, and molecular diagnostics.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next